Cargando…

CFO: Calibration-free odds design for phase I/II clinical trials

Recent revolution in oncology treatment has witnessed emergence and fast development of the targeted therapy and immunotherapy. In contrast to traditional cytotoxic agents, these types of treatment tend to be more tolerable and thus efficacy is of more concern. As a result, seamless phase I/II trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Huaqing, Yin, Guosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527856/
https://www.ncbi.nlm.nih.gov/pubmed/35238697
http://dx.doi.org/10.1177/09622802221079353

Ejemplares similares